Imagine getting a blood test by just pricking your finger at home instead of going to a clinic for a needle in the arm. This work creates a reliable system for collecting tiny amounts of blood that can be sent to labs from anywhere. It makes healthcare easier for people who can't travel and reduces the waste created by traditional medical visits.
Traditional blood sampling requires patients to visit clinics, creating barriers for vulnerable populations and increasing costs for healthcare providers. This leads to inefficient clinical trials and limited access to personalized monitoring.
A validated 'Gold Standard' workflow for blood microsampling and a set of harmonized regulatory and cost-benefit models for European adoption.
If you are a CRO dealing with high patient dropout rates in clinical trials — this project developed a validated workflow for microsampling that allows for decentralized trials. This reduces the burden on participants and increases trial accessibility.
If you are a diagnostics manufacturer dealing with a lack of clear rules for home-testing kits — this project developed harmonized regulatory and HTA pathways. This provides a clear map for getting microsampling products approved across Europe.
If you are a telehealth provider dealing with the gap between virtual consultation and physical testing — this project developed the logistics and tools to integrate microsampling into remote care. This enables a full end-to-end digital health experience.
The project is developing specific cost-benefit models and Health Technology Assessment (HTA) pathways to prove the economic viability of microsampling over traditional venipuncture. Based on available project data, these will be part of the harmonized European standards.
Yes, the project aims to create a 'Gold Standard' infrastructure and workflow designed to be a core healthcare tool across Europe. It involves 39 industry partners to ensure the solutions are scalable.
Based on available project data, the project focuses on creating a foundation for future access to scientific findings and tools to enable rapid uptake. Specific licensing terms are not detailed in the summary.
The project specifically addresses this by creating harmonized regulatory pathways and standards to make microsampling an acceptable alternative to venous blood-draw across Europe.
The project period runs from 2024-11-01 to 2028-04-30, meaning final validated workflows and regulatory pathways will be ready by April 2028.
It provides a tested infrastructure and workflow that allows microsampling to be integrated into decentralized trials and existing care pathways.
The consortium is heavily weighted toward commercial application, with a 70% industry ratio comprising 39 companies, including 12 SMEs. This strong private-sector presence, spanning 13 countries, suggests the project is focused on market adoption and regulatory compliance rather than pure academic research.
Contact ARISTOTELIO PANEPISTIMIO THESSALONIKIS for partnership inquiries.
Contact us to identify which of the 39 industry partners align with your technology stack.
